Alzheimer’s Breakthrough: First EU-Approved Treatment
- Published: april 16,2025,1:26 PM CET | Updated: April 16,2025,4:15 PM CET
- BRUSSELS — The European Commission has approved a new treatment for Alzheimer's disease,the most prevalent form of dementia.
- The decision follows an almost 18-month evaluation process, culminating in the Commission's endorsement based on a "positive scientific analysis" from the European Medicines agency (EMA).
European Commission Approves New Alzheimer’s Treatment
By Julia Tromp
Published: april 16,2025,1:26 PM CET | Updated: April 16,2025,4:15 PM CET
BRUSSELS — The European Commission has approved a new treatment for Alzheimer’s disease,the most prevalent form of dementia. This marks the first therapy aimed at slowing the progression of the debilitating illness.
Green Light After Lengthy Review
The decision follows an almost 18-month evaluation process, culminating in the Commission’s endorsement based on a “positive scientific analysis” from the European Medicines agency (EMA).
Previously, available medications only addressed Alzheimer’s symptoms temporarily, without impacting the underlying disease mechanism.
‘A Scientific Breakthrough’
The newly approved treatment aims too alter this,possibly delaying the advancement of Alzheimer’s in its early stages. Dinant Bekkenkamp, a researcher with Alzheimer Nederland, hailed the growth as “a scientific breakthrough.”
The treatment targets the accumulation of harmful proteins in the brain,a hallmark of Alzheimer’s disease.
The medication is designed to identify and break down these proteins. Clinical trials indicated that, after 18 months, treated patients experienced approximately 30% less disease progression compared to those who did not receive the treatment.
“Patients will not be cured, but their decline will be slowed,” Bekkenkamp stated. “This is truly novel.”
Amsterdam UMC Neurologist Involved in Testing
Neurologist Jort Vijverberg, associated with Alzheimercentrum Amsterdam at Amsterdam UMC, has been involved in testing the treatment. He is currently overseeing ten Alzheimer’s patients participating in a trial of the drug.
Patients undergo bi-weekly infusions for at least 18 months. Regular MRI scans monitor brain changes and potential side effects, such as swelling or bleeding. “It’s an intensive process, but my patients are keen,” Vijverberg said.
Treatment Limitations
While the approval is a positive step, the treatment is not suitable for all Alzheimer’s patients. Its use is restricted to a relatively small subset of individuals in the early stages of the disease and in generally good health.
Bekkenkamp noted that the treatment is not recommended for individuals with cardiovascular disease due to an increased risk of side effects. “The likelihood of side effects increases if someone already has other underlying conditions,” he explained.
Vijverberg estimates that between 15,000 and 20,000 patients in the Netherlands could potentially benefit from the treatment. Currently, over 200,000 peopel in the country are living with Alzheimer’s.
Reimbursement Uncertainty
Even with European Commission approval,the treatment’s availability in the Netherlands is not guaranteed. Zorginstituut Nederland, which advises the government on medical treatment reimbursement, must first decide whether to include the medication in insurance coverage.
“costs of 40,000 or even 50,000 euros per patient per year are being considered. That is ample,” Bekkenkamp said. “I fear that the Healthcare Institute will debate for a long time whether the costs outweigh the effectiveness.”
Neurologist Debate
Vijverberg acknowledged that there is ongoing discussion among neurologists regarding the treatment. Some express reservations, citing the limited target group and potential side effects.
Vijverberg hopes for a swift decision from the Healthcare Institute.The treatment is already available in countries like the United States and the United Kingdom. “At the hospital in Amsterdam, we are certainly prepared for it,” he concluded.
Treatment Limitations
While the approval is a positive step, the treatment is not suitable for all AlzheimerS patients. it’s use is restricted to a relatively small subset of individuals in the early stages of the disease and in generally good health.
Bekkenkamp noted that the treatment is not recommended for individuals with cardiovascular disease due to an increased risk of side effects. “The likelihood of side effects increases if someone already has other underlying conditions,” he explained.
Vijverberg estimates that between 15,000 and 20,000 patients in the Netherlands could potentially benefit from the treatment. Currently, over 200,000 peopel in the country are living with Alzheimer’s.
Reimbursement Uncertainty
Even with European Commission approval,the treatment’s availability in the Netherlands is not guaranteed. zorginstituut Nederland, which advises the government on medical treatment reimbursement, must first decide whether to include the medication in insurance coverage.
“costs of 40,000 or even 50,000 euros per patient per year are being considered. That is ample,” Bekkenkamp said. “I fear that the Healthcare Institute will debate for a long time whether the costs outweigh the effectiveness.”
Neurologist Debate
Vijverberg acknowledged that there is ongoing discussion among neurologists regarding the treatment. Some express reservations, citing the limited target group and potential side effects.
Vijverberg hopes for a swift decision from the Healthcare Institute.The treatment is already available in countries like the United States and the United Kingdom. “At the hospital in Amsterdam, we are certainly prepared for it,” he concluded.
.Progress logically, anticipating the questions a reader might have at each stage, guiding them through the topic and encouraging the reader to learn more.
Tone: Maintain a professional yet empathetic tone, avoiding overly technical jargon. Aiming for a “human touch” and conversational.
E-E-A-T Signals:
Credibility: ground all information in the context, facts, and data from the provided
Expertise: Demonstrate a solid understanding of the subject matter (Alzheimer’s treatment, medical approvals, etc.)
authoritativeness: Structure and present information clearly and concisely, establishing a strong voice on the topic.
Trustworthiness: Accurately represent facts and avoid speculation.
SEO Considerations:
Keywords: Naturally incorporate relevant keywords related to Alzheimer’s treatment,European Commission,and related terms.
Internal Linking: Identify opportunities for natural internal linking within the Q&A format.
Output:
New Alzheimer’s Treatment Approved in Europe: Your Questions Answered
By Julia Tromp
Published: April 16, 2025, 1:26 PM CET | Updated: April 16, 2025, 4:15 PM CET
The European Commission has approved a new treatment for Alzheimer’s disease. Hear’s what you need to know.
Frequently asked Questions
What is the new Alzheimer’s treatment that has been approved?
The European Commission has approved a new treatment aimed at slowing the progression of Alzheimer’s disease. It’s a significant advancement because it’s the first therapy designed to address the underlying disease mechanism, rather than just managing symptoms. According to the article, this marks the first therapy aimed at slowing the debilitating illness.
How was this treatment approved?
The approval followed an almost 18-month evaluation process by the European Medicines Agency (EMA). The Commission’s endorsement was based on a “positive scientific analysis” from the EMA.
What is the goal of the new treatment?
The treatment aims to potentially slow the advancement of Alzheimer’s, especially in its early stages. Dinant Bekkenkamp,a researcher with Alzheimer Nederland,called it a “scientific breakthrough”.
How does the treatment work?
The treatment targets the accumulation of harmful proteins in the brain, which is a hallmark of Alzheimer’s disease. The medication is designed to identify and break down thes proteins. Clinical trials have shown that patients experienced approximately 30% less disease progression after 18 months compared to those not receiving the treatment.
Will this treatment cure Alzheimer’s?
No, the treatment will not cure Alzheimer’s. Bekkenkamp stated that “Patients will not be cured, but their decline will be slowed.”.
Are there any doctors involved in the testing process?
Yes, Jort Vijverberg, a neurologist associated with Alzheimercentrum Amsterdam at Amsterdam UMC, has been involved in testing the treatment. He is currently overseeing ten Alzheimer’s patients participating in a trial of the drug.
Who is eligible to receive this treatment?
The article states that the treatment is not suitable for all Alzheimer’s patients. This treatment is restricted to a relatively small subset of individuals in the early stages of the disease and generally good health.
Are there any limitations or risks associated with the treatment?
Yes. According to the article, the treatment is not recommended for those with cardiovascular disease due to increased risk of side effects. Bekkenkamp said that the likelihood of side effects increases if someone already has other underlying conditions.
How many people could potentially benefit from this treatment?
Vijverberg estimates that between 15,000 and 20,000 patients in the Netherlands could be potential beneficiaries of this treatment. Currently, over 200,000 people in the Netherlands are living with Alzheimer’s.
Is this treatment available in the Netherlands?
Not yet.Although approved by the European Commission,the availability of the treatment in the Netherlands is not guaranteed. Zorginstituut Nederland,which advises the government on medical treatment reimbursement,must first decide whether to include the medication in insurance coverage. “Costs of 40,000 or even 50,000 euros per patient per year are being considered. That is ample,” Bekkenkamp said. “I fear that the Healthcare institute will debate for a long time whether the costs outweigh the effectiveness.”
What are neurologists saying about the treatment?
Vijverberg acknowledges that there is ongoing discussion among neurologists regarding the treatment. some express reservations, citing the limited target group and potential side effects.
Is this treatment available elsewhere?
Yes, the treatment is already available in countries like the united States and the United Kingdom.
Summary Table: Key Information about the New Alzheimer’s Treatment
| Aspect | Details |
|---|---|
| Treatment Goal | slow the progression of Alzheimer’s disease. |
| Mechanism | Targets and breaks down harmful proteins in the brain. |
| Approval Status | Approved by the European commission. |
| Eligibility | Limited to a subset of patients in early stages and good health. |
| Side Effects | Increased risk for those with cardiovascular disease. |
| Availability in Netherlands | Pending decision on reimbursement by Zorginstituut Nederland. |
| Expert Quote (Bekkenkamp) | “Patients will not be cured, but their decline will be slowed.” |
This new treatment offers a glimmer of hope for those affected by Alzheimer’s. While it is a welcome development, it is essential to understand its limitations and the need for further research and accessible healthcare policies.